1. |
Adjemian J, Daniel-Wayman S, Ricotta E, et al. Epidemiology of Nontuberculous Mycobacteriosis. Semin Respir Crit Care Med, 2018, 39(3): 325-335.
|
2. |
Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis, 2010, 16(10): 1576-1583.
|
3. |
中华医学会结核病学分会, 《中华结核和呼吸杂志》编辑委员会. 非结核分枝杆菌病诊断与治疗专家共识. 中华结核和呼吸杂志, 2012, 35(8): 572-580.
|
4. |
中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南(2018年). 中华全科医师杂志, 2019, 18(8): 709-717.
|
5. |
朱定俊, 曾玮, 屈世林, 等. 非结核分枝杆菌肺病误诊为肺结核8例分析. 长江大学学报(自科版), 2014, 11(24): 36-37.
|
6. |
Simons S, van Ingen J, Hsueh PR, et al. Nontuberculous mycobacteria in respiratory tract infections, Eastern Asia. Emerg Infect Dis, 2011, 17(3): 343-349.
|
7. |
Picchi H, Mateus C, Chouaid C, et al. Infectious complications associated with the use of immune checkpoint inhibitors in oncology: reactivation of tuberculosis after anti PD-1 treatment. Clin Microbiol Infect, 2018, 24(3): 216-218.
|
8. |
Barber DL, Sakai S, Kudchadkar RR, et al. Tuberculosis following PD-1 blockade for cancer immunotherapy. Sci Transl Med, 2019, 11(475): eaat2702.
|
9. |
Anastasopoulou A, Ziogas DC, Samarkos M, et al. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer, 2019, 7(1): 239.
|
10. |
Elkington PT, Bateman AC, Thomas GJ, et al. Implications of tuberculosis reactivation after immune checkpoint inhibition. Am J Respir Crit Care Med, 2018, 198(11): 1451-1453.
|
11. |
Lee JJ, Chan A, Tang T. Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. Acta Oncol, 2016, 55(4): 519-520.
|
12. |
. Lázár-Molnár E, Chen B, Sweeney KA, et al. Programmed death-1 (PD-1)-deficient mice are extraordinarily sensitive to tuberculosis. Proc Natl Acad Sci U S A. 2010, 107(30): 13402-13407.
|
13. |
Tousif S, Singh Y, Prasad DV, et al. T cells from programmed death-1 deficient mice respond poorly to Mycobacterium tuberculosis infection. PLoS One, 2011, 6(5): e19864.
|
14. |
许金卫, 张鑫, 陈震. 非结核分枝杆菌肺病与继发性肺结核的CT表现分析. 新发传染病电子杂志, 2020, 5(2): 113-117.
|
15. |
Sharma SK, Upadhyay V. Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases. Indian J Med Res, 2020, 152(3): 185-226.
|
16. |
Haworth CS, Banks J, Capstick T, et al. British Thoracic Society Guideline for the Management of Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD). BMJ Open Respir Res, 2017, 4(1): e000242.
|
17. |
Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med, 2007, 175(4): 367-416.
|